Jagsonpal Pharma (JAGSNPHARM)
STALWARTFairStock Score: 11/100 — RISKY
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹202.02 |
| Market Cap | ₹1,128.24 Cr |
| P/E Ratio | 26.48 |
| ROCE | 22.95% |
| ROE | 20.75% |
| Dividend Yield | 1.48% |
| Profit Growth | -8.43% |
| Debt/Equity | 0.03 |
| Sales Growth | -1.46% |
| Promoter Holding | 67.39% |
| 52-Week Range | ₹155 — ₹301.65 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹29.2 |
Jagsonpal Pharma trades with a P/E ratio of 26.48, ROCE of 22.95%, ROE of 20.75%, profit growth of -8.43%, debt-to-equity of 0.03. The FairStock Score of 11/100 flags concerns across multiple fundamental dimensions that investors should examine carefully.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer